Track 1, Day 3
While innovative precision technologies can improve patient outcomes; they present new information and price shocks to payers. Emerging clinical guidelines may add to the confusion and further hamper payer acceptance. During this session, we’ll explore payer perspectives in the evidence evaluation processes that guide coverage decisions.
Session Chair Profile
PHARMD, President, ASP
Biography
Sara Rogers co-founded the American Society of Pharmacovigilance and co-led the formation of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, a public-private multidisciplinary initiative to develop consensus-based industry standards for pharmacogenetics testing. She joined Texas A&M University in 2021, where she holds joint appointments with Institute of Biosciences and Technology, School of Medicine and Irma Lerma Rangel School of Pharmacy. Rogers co-chairs the Pharmacogenomics Access and Reimbursement Coalition and collaboratively develops the Coalition’s research agenda to understand the payment and policy landscape for pharmacogenetics testing and its role in disparities in patient access. Rogers is an organizational member of the NIH NHGRI Inter-Society Coordinating Committee and develops educational resources to help practitioners navigate coverage for pharmacogenetics testing. Rogers has served as co-investigator for a pilot study to identify ethical values and priorities related to pharmacogenomics. Her research focuses extensively on patient access to and reimbursement for pharmacogenetics testing.
Talk
While innovative precision technologies can improve patient outcomes; they present new information and price shocks to payers. Emerging clinical guidelines may add to the confusion and further hamper payer acceptance. During this session, we’ll explore payer perspectives in the evidence evaluation processes that guide coverage decisions.
Speaker Profile
Product Director of Pharmacogenomics, Optum Rx
Biography
Ray currently works at Optum Rx within the Product & Strategy organization. Over the past 4 years he has been charged to explore the space of Pharmacogenomics, and how it could be utilized within the Pharmacy Benefit Manager space. In this work he has helped conduct 4 pilots and 1 clinical study. These studies have been targeted toward answering the companies killer questions. The last of which is what the clinical study was looking to answer, which is will the use of PGx drive down the total cost of care for a utilizing member. Ray has been at UnitedHealth Group for the better part of 15 years with roles Marketing, Research & Development, Operations, and Product Development.
Speaker Profile
Ph.D., Professor / CSO, UBC
Biography
Stirling Bryan is a health economist with a passion for building and supporting patient-oriented learning health systems. Before emigrating to Canada in 2008, Stirling held academic positions in the U.K. at St Thomas’ Hospital, Brunel University, and the University of Birmingham. He was a Commonwealth Fund Harkness Fellow in 2005/06, spending a year at Stanford University, and in 2020 was elected as a Fellow of the Canadian Academy of Health Sciences.
